Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Summary

This study will assess the effectiveness of CP- 751,871 when given in combination with docetaxel to women with the first occurrence of advanced breast cancer disease. The effectiveness will be measured by progression-free survival duration. Patients will be followed for 2 years from the date of randomization.

Timeline

Start

2009-04

Primary completion

2011-09

Completion

2011-09

Drugs

Indications